Efficient Gene Editing at Major CFTR Mutation Loci
dc.contributor.author | Ruan, J | |
dc.contributor.author | Hirai, H | |
dc.contributor.author | Yang, D | |
dc.contributor.author | Ma, L | |
dc.contributor.author | Hou, X | |
dc.contributor.author | Jiang, H | |
dc.contributor.author | Wei, H | |
dc.contributor.author | Rajagopalan, C | |
dc.contributor.author | Mou, H | |
dc.contributor.author | Wang, G | |
dc.contributor.author | Zhang, J | |
dc.contributor.author | Li, K | |
dc.contributor.author | Chen, YE | |
dc.contributor.author | Sun, F | |
dc.contributor.author | Xu, J | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-10-05T14:55:22Z | |
dc.date.available | 2022-10-05T14:55:22Z | |
dc.date.issued | 2019-06-07 | |
dc.identifier.issn | 2162-2531 | |
dc.identifier.issn | 2162-2531 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/30852378 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/174898 | en |
dc.description.abstract | Cystic fibrosis (CF) is a lethal autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Nuclease-mediated precise gene editing (PGE) represents a promising therapy for CF, for which an efficient strategy that is free of viral vector, drug selection, and reporter enrichment (VDR free) is desirable. Here we compared different transfection methods (lipofectamine versus electroporation) and formats (plasmid DNA versus ribonucleoprotein) in delivering the CRISPR/Cas9 elements along with single-stranded oligodeoxynucleotides (ssODNs) to clinically relevant cells targeting major CFTR mutation loci. We demonstrate that, among different combinations, electroporation of CRISPR/Cas9 and guide RNA (gRNA) ribonucleoprotein (Cas9 RNP) is the most effective one. By using this VDR-free method, 4.8% to 27.2% efficiencies were achieved in creating dF508, G542X, and G551D mutations in a wild-type induced pluripotent stem cell (iPSC) line. When it is applied to a patient-derived iPSC line carrying the dF508 mutation, a greater than 20% precise correction rate was achieved. As expected, genetic correction leads to the restoration of CFTR function in iPSC-derived proximal lung organoids, as well as in a patient-derived adenocarcinoma cell line CFPAC-1. The present work demonstrates the feasibility of gene editing-based therapeutics toward monogenic diseases such as CF. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | Elsevier | |
dc.rights | Licence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Stem Cell Research | |
dc.subject | Stem Cell Research - Induced Pluripotent Stem Cell | |
dc.subject | Lung | |
dc.subject | Cystic Fibrosis | |
dc.subject | Rare Diseases | |
dc.subject | Stem Cell Research - Induced Pluripotent Stem Cell - Human | |
dc.subject | Regenerative Medicine | |
dc.subject | Genetics | |
dc.subject | Gene Therapy | |
dc.subject | Biotechnology | |
dc.subject | 5.2 Cellular and gene therapies | |
dc.subject | 5 Development of treatments and therapeutic interventions | |
dc.subject | Congenital | |
dc.title | Efficient Gene Editing at Major CFTR Mutation Loci | |
dc.type | Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/174898/2/Efficient Gene Editing at Major CFTR Mutation Loci.pdf | |
dc.identifier.doi | 10.1016/j.omtn.2019.02.006 | |
dc.identifier.doi | https://dx.doi.org/10.7302/6527 | |
dc.identifier.source | Molecular Therapy - Nucleic Acids | |
dc.description.version | Published version | |
dc.date.updated | 2022-10-05T14:55:19Z | |
dc.identifier.orcid | 0000-0003-2449-8651 | |
dc.identifier.orcid | 0000-0003-2357-7825 | |
dc.identifier.volume | 16 | |
dc.identifier.startpage | 73 | |
dc.identifier.endpage | 81 | |
dc.identifier.name-orcid | Ruan, J | |
dc.identifier.name-orcid | Hirai, H | |
dc.identifier.name-orcid | Yang, D; 0000-0003-2449-8651 | |
dc.identifier.name-orcid | Ma, L | |
dc.identifier.name-orcid | Hou, X | |
dc.identifier.name-orcid | Jiang, H | |
dc.identifier.name-orcid | Wei, H | |
dc.identifier.name-orcid | Rajagopalan, C | |
dc.identifier.name-orcid | Mou, H | |
dc.identifier.name-orcid | Wang, G | |
dc.identifier.name-orcid | Zhang, J | |
dc.identifier.name-orcid | Li, K | |
dc.identifier.name-orcid | Chen, YE; 0000-0003-2357-7825 | |
dc.identifier.name-orcid | Sun, F | |
dc.identifier.name-orcid | Xu, J | |
dc.working.doi | 10.7302/6527 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.